Trojan Lutz, Michel Maurice Stephan, Rensch Florian, Jackson David G, Alken Peter, Grobholz Rainer
Department of Urology, University Hospital Mannheim, Mannheim, Germany.
J Urol. 2004 Jul;172(1):103-7. doi: 10.1097/01.ju.0000128860.00639.9c.
Due to the lack of specific markers the analysis of lymphatic vessel density (LVD) has been almost impossible in the past. We report the novel specific marker for lymphatic endothelium, lymphatic vessel endothelial hyaluronan receptor (LYVE-1), in prostatic, benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissue. Normal blood vessels were additionally quantified in BPH and PCa.
LYVE-1 lymphatics (LVD) and CD34 blood vessels were assessed in 20 paraffin sections of BPH and 50 of PCa tissue by immunohistochemistry in a standardized experimental setting. The regions of PCa, periphery of the tumor and nontumorous regions of the PCa specimens, and BPH tissue were evaluated. Double staining was done (LYVE-1/CD34). Acquired data were interrelated and compared to the pathological parameters of the specimens.
Double staining revealed numerous CD34 blood vessels but only a few LYVE-1 lymphatic vessels in BPH and PCa sections. Mean LVD +/- SD was distinctly lower (0.55 +/- 0.93) in PCa tissue than in tumor periphery (2.45 +/- 1.93) and nontumorous (3.16 +/- 2.23) tissue (p <0.0001). Maximum LVD was observed in BPH (7.17 +/- 3.61), which differed markedly from nontumorous areas of PCa specimens (p <0.001). In contrast to LVD, significantly more blood vessels were found in PCa (116.00 +/- 39.25) than in BPH (60.30 +/- 19.34) tissue (p <0.001).
LYVE-1 is a specific lymphatic endothelial marker in benign and malignant prostate tissues. It is a useful new marker for the investigation of lymphatics. To our knowledge we report the immunohistochemical visualization and quantification of lymphatic vessels in prostatic tissue for the first time. In contrast to the stimulated angiogenesis of blood vessels in PCa, the destruction of lymphatic vessels occurs rather than lymphangiogenesis.
由于缺乏特异性标志物,过去几乎无法对淋巴管密度(LVD)进行分析。我们报告了一种用于淋巴管内皮的新型特异性标志物——淋巴管内皮透明质酸受体(LYVE-1),并对前列腺组织、良性前列腺增生(BPH)组织和前列腺癌(PCa)组织进行了研究。此外,还对BPH和PCa中的正常血管进行了定量分析。
在标准化实验条件下,通过免疫组织化学方法对20例BPH石蜡切片和50例PCa组织石蜡切片中的LYVE-1淋巴管(LVD)和CD34血管进行评估。对PCa区域、肿瘤周边以及PCa标本的非肿瘤区域和BPH组织进行了评估。进行了双重染色(LYVE-1/CD34)。将获取的数据进行关联,并与标本的病理参数进行比较。
双重染色显示,在BPH和PCa切片中,有大量CD34血管,但LYVE-1淋巴管数量较少。PCa组织中的平均LVD±标准差(0.55±0.93)明显低于肿瘤周边(2.45±1.93)和非肿瘤组织(3.16±2.23)(p<0.0001)。BPH中的LVD最大值(7.17±3.61),与PCa标本的非肿瘤区域有显著差异(p<0.001)。与LVD相反,PCa组织(116.00±39.25)中的血管数量明显多于BPH组织(60.30±19.34)(p<0.001)。
LYVE-1是良性和恶性前列腺组织中的特异性淋巴管内皮标志物。它是研究淋巴管的一种有用的新标志物。据我们所知,我们首次报道了前列腺组织中淋巴管的免疫组织化学可视化和定量分析。与PCa中血管的促血管生成相反,淋巴管发生破坏而非淋巴管生成。